INTRODUCTION
Mitotic spindle assembly is a highly complex and orchestrated event that organizes cell division. Mitosis relies on a multitude of protein complexes, protein-protein interactions, and regulatory mechanisms (Walczak and Heald, 2008) . To date, many proteins that associate with microtubules and function in mitotic spindle assembly have been identified and characterized (Loughlin et al., 2008; Compton, 2008a, 2008b; Walczak and Heald, 2008) . Nonmotor proteins, for example, function in microtubule nucleation, crosslinking, and stability, and they can influence the activities of motor proteins (Manning and Compton, 2008b) . Motor proteins, in addition to their transport roles, influence microtubule dynamics, kinetochore microtubule attachment, and centrosome separation (Walczak and Heald, 2008) .
A strategy in the treatment of cancer has been to inhibit cell division with antimitotic drugs, a set of natural and synthetic small molecules that characteristically arrest cells in mitosis, and induce programmed cell death (Gascoigne and Taylor, 2008; Shi et al., 2008) . The spindle is the major target of antimitotics and three major microtubule spindle targets and associated inhibitors have been explored in the clinic: microtubule inhibitors including taxanes and epothilones; inhibitors of the Polo-like kinase Plk1, a regulator of spindle assembly, including BI 2536; and inhibitors of the mitotic kinesin-5, including monastrol and ispinesib (Kapoor et al., 2000; Lansing et al., 2007) . Recent clinical trials have questioned the long-term efficacy of current antimitotic drugs. Although taxol remains the most widely-used and efficacious chemotherapeutic agent, it shows dose-limiting toxicities, including neutropenia and severe neuropathies, driving a need to identify alternative antimitotic drug targets that can be targeted and combined with lower doses of taxol to reduce the toxicity associated with high-dose taxol.
To identify proteins involved in mitotic spindle assembly, the linkage to cell death, and thus uncover potential targets for cancer therapeutics, we performed a proteomic analysis to identify mitotic microtubule copurifying proteins (MMCPs) and genetic RNAi screening to test the contribution of these proteins to mitotic progression and induction of apoptosis. We report the results of these screens, which we exemplify by the identification and characterization of STARD9, a mitotic kinesin. STARD9 is necessary for PCM cohesion during the establishment of spindle bipolarity. The absence of STARD9 causes the pericentriolar material to fragment and dissociate from the centrioles, along with a failure to congress chromosomes, multipolar spindle formation, mitotic arrest, and apoptotic cell death. Most importantly, depletion of STARD9 synergizes with taxol treatment, making STARD9 a candidate target to extend current cancer therapeutics.
RESULTS

Identification of Mitotic Microtubule Copurifying Proteins
To identify MMCPs that contribute to mitotic spindle formation, we performed a proteomic analysis of microtubule aster copurifying proteins ( Figures 1A-1D ). Mitotic HeLa cell extracts were induced to undergo in vitro microtubule polymerization in the presence or absence of the microtubule-stabilizing drug, taxol (see Mack and Compton, 2001 ) ( Figure 1B ). Polymerized microtubules and associated proteins were purified by sedimentation through a sucrose cushion. The selectivity of the purification was assessed by immunoblotting protein samples from the supernatant (S) and the pelleted microtubule aster (P) fractions for Kinesin-5 and cyclin D ( Figure 1C ). Kinesin-5 associated with the taxol stabilized microtubule pellet, whereas cyclin D remained in the supernatant ( Figure 1C ). Neither protein pelleted in the absence of taxol, demonstrating minimal nonspecific pelleting ( Figure 1C ). Purified microtubule asters were trypsinized in solution and 592 MMCPs were identified by mass spectrometry (LC-MS/MS) ( Figure 1D , Table S1 , and Supplemental Information available online).
To understand the potential roles of these proteins in cell division, the 592 MMCPs were systematically queried in PubMed and one of eight functional annotations was assigned to each protein based on existing literature ( Figure 1E and Table S1 ). 25% of the proteins had a previously validated role in microtubule dynamics and stability, including TPX2, NuMA, and Astrin. Another 14% were involved in spindle-associated activities, including spindle checkpoints, kinetochore-microtubule attachment, centrosome homeostasis, regulation of mitosis, or were microtubule-based molecular motors including kinesins. Interestingly, over half of the proteins were either uncharacterized or had not been linked to mitotic spindle assembly ( Figure 1E and Table S1 ).
The domain compositions of the 592 MMCPs were analyzed by querying the Unison (http://unison-db.org) (Hart Tables S1 and S2. and Mukhyala, 2009) database, which calculates the presence of domains from the Pfam (Finn et al., 2008) and Prosite (Hulo et al., 2006) databases, as well as from signal sequence and transmembrane prediction algorithms (see Extended Experimental Procedures). Proteins and domains were hierarchically clustered (Eisen et al., 1998) using the Pearson correlations of the numbers of each domain appearing in each protein (Tables S1 and S2) . A notable cluster of 21 MMCPs contained kinesin motor domains, including an uncharacterized protein STARD9, a family of ATPases whose members are important for spindle bipolarity, spindle pole focusing, kinetochore function, and regulation of microtubule dynamics.
Functional Characterization of MMCPs
To assess the contribution of MMCPs to mitotic progression, we developed a siRNA library targeting the knockdown of all MMCP-encoding genes ( Figure 1F ). The library was used to perform four functional screens: mitotic arrest; mitotic spindle assembly checkpoint (SAC) bypass; induction of apoptosis; and synergy with taxol to induce apoptosis (Figures 2A-2H,  Table S3 , Supplemental Information). Due to space constraints we focus our discussion on two screens. First, we sought to identify gene depletions leading to mitotic arrest. HeLa cells were reverse transfected with siRNAs for 48 hr prior to fixation and staining with Hoechst (DNA dye) and anti p-H3 antibodies, which recognize phosphorylated histone H3 (a marker of mitotic cells). Data was collected on 1,000 Hoechst positive cells per well using an image-based, high-content screening microscope. The mitotic index (MI) per well was derived from the number of mitotic nuclei (p-H3 positive) divided by the total nuclei (Hoechst positive) ( Figure 2B ). The results were graphed as scatter plots, with normalized MI on the y axis (in log scale) and individual oligonucleotides spread across the x axis. 194 siRNAs, corresponding to 138 genes showed an increased MI greater than two standard deviations from the mean, and within this set 32 genes had two or more oligonucleotides score as hits ( Figure 2C and Table S3 ). The majority of these gene products had a validated role in spindle assembly like TOGp, TPX2, TACC3, and Kinein-5. Additionally, this set also included multiple proteins with potential roles in spindle assembly, like STARD9. Next, we screened for gene depletions leading to apoptosis ( Figure 2E-2H ). Apoptosis relies on caspase 3/7 activity (Chowdhury et al., 2008) . Therefore, we used a luciferase-based assay (caspase substrate linked to luciferin, which when cleaved is converted to light by luciferase and can be measured by a luminometer) to measure total caspase 3/7 activities (Caspase-Glo assay) per well. Additionally, the CellTiter-Glo assay, which measures total ATP levels (indicative of metabolically active cells) was used to measure the number of viable cells per well. HeLa cells were transfected with siRNA and the apoptotic index (AI, caspase activity per cell/ATP levels as described in (Peterson et al., 2010) was measured 72 hr posttransfection ( Figure 2F ). Depletion of 45 genes (with R 2 oligonucleotides scored as hits) showed an increased AI one standard deviation above the mean ( Figure 2G ). Among this set were Plk1, NuMA, AF15Q14, and STARD9.
Identification of STARD9
When inhibited, antimitotic targets arrest cells in mitosis and induce apoptosis (Gascoigne and Taylor, 2008; Shi et al., 2008) . To assess the potential of MMCPs as antimitotic drug targets, we performed a correlation analysis of the normalized MI and normalized AI for each oligonucleotide from our screens ( Figure 2I ). This separated data into 4 quadrants, including a quadrant with 39 genes whose depletion caused an increase in both MI and AI ( Figures 2I and 2J ). This quadrant included Plk1 and Kinesin-5 whose depletion have been previously demonstrated to both induce mitotic arrest and activate the apoptotic response (Petronczki et al., 2008; Shi et al., 2008) (Figure 2J ). Within this set we identified STARD9 (steroidgenic acute regulatory protein-related lipid transfer (START) domain containing 9), a previously uncharacterized kinesin-like protein (Halama et al., 2006) (Figure 2J ). STARD9 was selected for further analysis, based on its copurification with mitotic microtubule asters, requirement for mitotic progression, role in suppressing apoptosis, and novelty as a mitotic kinesin.
STARD9 Is a Kinesin-3 Family Member
Database searches predicted three STARD9 isoforms; the longest encoding a 4,614 amino acid protein with an apparent molecular mass of 506.7 kDa (Figures S1A, S1B, and 3A). STARD9 is a member of the Kinesin-3 family, and shares 52% and 48% sequence identity within the motor domain (amino acids 1-374) with its closest human paralogues KIF16B and KIF1A respectively (Lawrence et al., 2004; Wickstead and Gull, 2006) (Figure 3B ). The Kinesin-3 family (composed of the KIF1, KIF13, KIF14, KIF16, and KIF28 subfamilies) is implicated in transporting vesicles and organelles (Hoepfner et al., 2005; Miki et al., 2005; Nangaku et al., 1994) . The STARD9 motor and FHA domains are conserved among all family members (Vale, 2003) . STARD9 also has a C-terminal START domain predicted to bind phospholipids and/or sterols, analogous to the KIF1A/KIF1B PH domain and the KIF16B PX domain that bind phospholipids (Alpy and Tomasetto, 2005) . Interestingly, STARD9 has a unique 26 amino acid residue insertion in loop 12, a microtubule interaction region of kinesins ( Figure 3B ). STARD9 is ubiquitously expressed at low levels in all tissues analyzed, including skin, brain, and heart ( Figure S1C ). Additionally, STARD9 orthologs are only found in vertebrates ( Figure S2 ).
STARD9 Localizes to Daughter Centrioles during Mitosis
To assess the role of STARD9 in mitosis, we analyzed its subcellular localization through the cell cycle. HeLa cells were fixed and costained for DNA, STARD9, and a-tubulin. STARD9 was distributed throughout the nucleus and cytoplasm in interphase, localized to the centrosomes from prophase to late anaphase, and disappeared at cytokinesis ( Figure 3C , see arrows). To define the localization of STARD9, we performed colocalization studies with centrosome and spindle pole markers ( Figure 3D ). Centrin staining detects two centrioles per centrosome and STARD9 consistently colocalized to one of the two centrioles ( Figure 3D, panel 1 zoom) . STARD9 also colocalized with pericentrin and g-tubulin and localized to the outer periphery of the spindle pole as defined by NUMA, TPX2, and Kinesin-5 staining ( Figure 3D , panels 2-6 zoom). Interestingly, STARD9 colocalized with centrobin, a notable daughter centriole-associated protein ( Figure 3E , see zoom) (Zou et al., 2005) . Thus, the localization of STARD9 to daughter centrioles is cell-cycle specific. Additionally, in cells containing multiple centrosomes, STARD9 only localized to the daughter centrioles of two centrosomes ( Figure S3A ), suggesting that it is under a restrictive control that blocks its appearance at supernumerary centrioles.
The STARD9 Motor Domain Contains Microtubule
Binding and ATPase Activities STARD9 is a kinesin-like protein with no previous molecular dissection, thus we analyzed whether GST-tagged STARD9 motor domain (MD) fusion proteins, wild-type (WT) and mutants could bind microtubules and undergo an ATPase cycle, two defining properties of kinesins. Mutant T110N is a threonine to asparagine substitution at position 110 within the P loop of the ATP binding site, predicted to show rigor binding to microtubules with no ATP hydrolysis or movement (Blangy et al., 1998) . Mutant R223A is an arginine to alanine substitution within the Switch I region, predicted to reduce its affinity for microtubules (Yun et al., 2001 ). For microtubule binding assays (as described in Goode and Feinstein, 1994) , MD-WT and MD mutants were incubated with or without polymerized microtubules and their ability to bind microtubules was determined by pelleting microtubules at 100,000 3 g and analyzing samples from the pellet and supernatant by SDS-PAGE and Coomassie blue staining ( Figure 4A ). Similar to microtubule associated protein 2 (Map2, positive control) MD-WT and MD-T110N pelleted with microtubules. However, MD-R223A showed a significantly reduced ability to pellet with microtubules ( Figure 4A ). Next, the ATPhydrolyzing activity of STARD9 was analyzed by performing ATPase assays (enzyme linked inorganic phosphate assay, Cytoskeleton Inc.) in the presence or absence of microtubules ( Figure 4B ). In this assay ATP hydrolysis releases inorganic phosphate (Pi), which is converted into an absorbance shift from 330 to 360 nm that can be measured by a spectrophotometer (Webb, 1992) . Similar to kinesin heavy chain, MD-WT displayed microtubule-stimulated ATPase activity. However, MD-T110N and Skp1 (negative control) showed minimal ATPase activity ( Figure 4B ). Therefore, the motor domain of STARD9 possesses microtubule binding and ATP hydrolyzing activities comparable to that of other kinesins.
Kinesins rely on their microtubule binding and ATP hydrolyzing activities to localize to specific subcellular structures. Thus, we analyzed whether STARD9s localization to centrioles was dependent on these activities. EGFP-tagged MD-WT, MD-T110N, and MD-R223A were expressed in HeLa cells and their localization was monitored by immunofluorescence. EFGP-MD-WT localized to the daughter centriole, consistent with endogenous STARD9 localization, along with the mother centriole and the surrounding PCM, indicating that this truncated fragment lacked determinants that selectively target it to the daughter centriole ( Figure 4C ). Consistently, GST-MD-WT, but not a control GST-Skp1, was able to bind a-tubulin and the centrosomal proteins g-tubulin, pericentrin, and MCAK in capture assays with purified centrosomes ( Figure 4D ). However, eGFP-MD-T110N and -MD-R223A were unable to localize to centrosomes ( Figure 4C ). These data indicate that the STARD9 microtubule binding and ATP hydrolyzing activities are required for its localization to centrosomes.
Depletion of STARD9 Induces PCM Fragmentation in Varied Cancer Cell Lines
To understand the role of STARD9 in mitosis, we analyzed the cellular consequences of depleting STARD9. First, we identified two siRNA oligonucleotides, which reduced STARD9 mRNA levels to less than 10% (oligonucleotides 1 (herein referred to as siSTARD9) and 4) ( Table S4 ). HeLa cells were transfected with siSTARD9 for 48 hr and the effect on mitosis was analyzed by costaining for DNA, centromeres, and a-tubulin ( Figure 5A ). STARD9-depleted cells failed to congress mitotic chromosomes, which remained scattered along a defective multipolar spindle ( Figure 5A ). Consistently, no STARD9 daughter centriole staining was observed in siSTARD9 cells, showing the specificity of these antibodies for STARD9 ( Figure S3B ). Similar defects were observed with STARD9 siRNA oligonucleotide 4 ( Figures  S3C and S3D) .
Multiple pathways exist for generating multipolar spindles, including centrosome amplification, centriole fragmentation, centriole splitting, and pericentriolar material (PCM) fragmentation (Fukasawa, 2007; Oshimori et al., 2006) . To define the mechanism(s) by which siSTARD9 cells generate multipolar spindles, we visualized the status of the centrosomes, centrioles (centrin) and PCM (pericentrin). Similar to siControl cells, mitotic siSTARD9 cells had two centrosomes with no centriole splitting or fragmentation ( Figure 5B ). In interphase, > 90% of siControl and siSTARD9 cells had one or two pericentrin or g-tubulin foci, indicating that STARD9 depletion did not trigger centrosome over-duplication ( Figures 5C and 5D ). In mitosis, 82% of siSTARD9 cells had more than two pericentrin foci, which correspond to sites of ectopic microtubule nucleation, compared to 12% of siControl cells ( Figures 5C and 5D ). These results indicate that siSTARD9 cells enter mitosis with a normal number of centrosomes and also suggest that multipolar spindles do not arise from centriole splitting or centriole fragmentation, but instead from fragmentation and dissociation of the PCM from centrosomes.
Our analysis of STARD9 centered on HeLa (cervical adenocarcinoma) cells, but we sought to assess the importance of STARD9 for cell division in other types of cancers. Thus, we analyzed the consequences of depleting STARD9 in a panel of cancer cell lines. Similar to the defects observed in HeLa cells, HCT116 (colorectal carcinoma), H460 (non-small cell lung (G and H) Apoptosis screens summary scatter plots for individual oligonucleotides ± taxol. x axis indicates oligonucleotides and y axis indicates normalized AI. :. * . *** ***********.: *: **.******.*** ***:**: carcinoma), and M-395 (melanoma) cells showed an increase in the number of mitotic cells with greater than 2 pericentrin foci ( Figures 5E and S4 ). In contrast, only a small increase in PCM fragmentation was observed in U2OS (bone osteosarcoma) and MCF-7 (breast adenocarcinoma) cells and no significant change was seen in hTERT-RPE-1 (retinal pigment epithelial cells, which have properties of more normal cells, and show strongly reduced responses to other antimitotic agents), (B) STARD9 motor domain alignment. The STARD9 motor domain shares 49% identity to KIF1A and 52% identity to KIF16B. A conserved insertion within loop 3 of Kinesin-3 family members is highlighted in green. Sequence C-terminal to motor domain, highlighted in blue, contains polarity determining amino acids residues and key residues predicting plus end directionality are in red. Figures 5E and S4 ). These results indicate that various cancer cells are sensitive to STARD9 depletion, but not normal cells. However, cancer subtypes tend to have varied genetic backgrounds, checkpoint competencies, and sensitivities to drug treatments. Therefore, we analyzed the response to STARD9 depletion in two panels of cancer cell lines, one containing 10 melanoma cell lines and the other 10 non-small cell lung carcinoma (NSCLC) cell lines. Surprisingly, only three out of ten melanoma and three out of ten NSCLC cell lines displayed PCM fragmentation above 55% ( Figure 5F ). Thus, although many types of cancer cells are sensitive to STARD9 depletion, there is a need to identify the specific subtypes. Deregulating the levels of microtubule-associated proteins can contribute to tumor formation, for example, TOGp, NuMA, and TPX2, which nucleate, crosslink, and stabilize microtubules in mitosis are overexpressed in cancer and correlate with a high incidence of chromosomal instability (Carter et al., 2006) . Additionally, RASSF1A and MTUS1, which control mitotic progression, are underexpressed in specific cancers and act as tumor suppressors (Rodrigues-Ferreira et al., 2009; Song et al., 2004) . Thus, we asked if proteins within the MMCP set (including STARD9) were deregulated in cancer by analyzing the differential gene expression levels of the MMCP set across 27 cancer tissues versus normal samples from the same tissue ( Figure S5 and Table S5 ). Consistent with previous studies, the spindle checkpoint regulators Mad2L1, Bub1, and Aurora kinase B (AurKB) clustered within a large group showing overexpression across multiple cancer types. This set included genes involved in centrosome (AurKA and Plk4) and spindle pole (Astrin) homeostasis, suggesting that spindle poles show altered regulation in cancer. Interestingly, STARD9 clustered with a large group downregulated across multiple cancer types that included the centriolar and ciliary protein Alms1 ( Figure S5 and Table S5 ). Consistently, qRT-PCR analysis showed that STARD9 was expressed at low levels in most cancers ( Figure 5G ). However, we found no simple correlation between the basal STARD9 expression levels and the extent of PCM fragmentation induced by STARD9 depletion.
MCF-10a (normal breast cells), lymphoblasts, and fibroblasts (
Overexpression of the STARD9 Motor Domain Partially Rescues PCM Fragmentation in STARD9-Depleted Cells
Possibly due to its large size, our attempts to express full length STARD9 were unsuccessful. As the STARD9 motor domain has microtubule binding and ATPase activities required for its localization to centrosomes, we asked if expression of the motor domain rescued the PCM fragmentation phenotype observed in STARD9-depleted cells. HeLa cells were cotransfected with siSTARD9 and siRNA resistant eGFP-tagged MD-WT, MD-T110N, and MD-R223A for 48 hr and the extent of PCM fragmentation was determined. Overexpression of MD-WT, but not MD-T110N or MD-R223A led to a modest but significant rescue (10%, p value .001; Figure 5H ), indicating that the STARD9 motor domain not only localizes STARD9 to centrioles, but also functions to maintain PCM cohesion. Interestingly, overexpression of MD-WT in control HeLa cells led to a modest increase (9%, p value .0491) in PCM fragmentation and mitotic spindle defects, indicating a dominant negative effect ( Figure 5I ).
STARD9 Is Not Required for Recruitment of Spindle Pole Focusing Activities
Kinesins are often involved in the transport of cargo along microtubules, therefore it was possible that STARD9s role in PCM cohesion involved the transport of factors required for centrosome homeostasis. Thus, we analyzed whether depletion of STARD9 had an effect on the localization of proteins involved in centrosome maturation (NEK2, AurKA, and Plk1), centrosome separation (Kinesin-5), microtubule nucleation (TPX2) and spindle organization (NuMA) by immunofluorescence microscopy. NEK2, AurKA, Plk1, Kinesin-5, NuMA, and TPX2 were each localized to spindle poles and ectopic microtubule nucleating sites (fragmented PCM) that formed multipolar spindles in siSTARD9 cells ( Figures 6A-6C and S6A-S6C). These results indicate that STARD9 does not recruit spindle pole focusing activities and motors necessary for spindle bipolarity.
Depletion of STARD9 Arrests Cells in Mitosis
with an Active SAC Depletion of STARD9 led to defects in chromosome congression and arrested cells in early mitosis, indicative of an activated spindle assembly checkpoint (SAC), which monitors microtubulekinetochore attachment and inter-kinetochore tension. When active, SAC proteins like BubR1 and Bub1 reside at the kinetochore region and disperse upon proper microtubule-kinetochore attachment (Musacchio and Salmon, 2007) . Consistently, siControl cells aligned their chromosomes at the metaphase plate with minimal BubR1 and Bub1 staining ( Figures 6D and  S6D) . Conversely, siSTARD9 cells arrested in prometaphase with BubR1 and Bub1 prominently localized to kinetochores ( Figures 6D and S6D) . The chromosomal passenger complex (CPC, composed of AurKB, INCENP, Survivin, and Borealin) is a SAC complex required to arrest cells in response to lack of inter-kinetochore tension (Ruchaud et al., 2007) . At the onset of anaphase, in siControl cells, the CPC was dynamically Tables S4 and S5. delocalized from the kinetochores and transitioned to the central spindle ( Figure 6E ). In contrast, in siSTARD9 cells, AurKB and INCENP remained at the kinetochore region and never redistributed to the central spindle ( Figures 6E and S6E) . These results indicate that STARD9-depleted cells lack proper microtubulekinetochore attachments and/or inter-kinetochore tension, which activates the SAC and arrests cells in early mitosis.
Chemical Inhibition of Cdk1, Plk1, or Kinesin-5 Function Prevents PCM Fragmentation in STARD9-Depleted Cells To define the timing and order of events leading to PCM fragmentation and mitotic arrest in siSTARD9 cells, we combined siSTARD9 treatment with inhibition of mitotic regulators. Synchronized siControl and siSTARD9 cells were treated with small molecule inhibitors of Plk1 (centrosome maturation), Kinesin-5 (centrosome separation), Cdk1 (G2/M transition), and microtubule dynamics (taxol and nocodazole) prior to mitotic entry. Two hours postmitotic entry, cells were fixed and costained for DNA, a-tubulin, pericentrin or centrin, and STARD9. Inhibition of Plk1 with the ATP-competitive inhibitor compound 1 (Lansing et al., 2007) arrested siControl and siSTARD9 cells with monopolar spindles and a focused PCM around the two centriole pairs ( Figure S7A, top panels) . Similarly, inhibition of Kinesin-5 with monastrol (Kapoor et al., 2000) arrested siControl and siSTARD9 cells with monopolar spindles and a matured PCM around the two centriole pairs ( Figure S7B , top panels). Thus, both treatments blocked siSTARD9 cells from transitioning to PCM fragmentation, indicating that STARD9 functions to maintain PCM cohesion downstream of centrosome maturation and separation. Consistent with this possibility, inhibition of Cdk1 with RO-3306 (Vassilev et al., 2006) arrested cells at the G2/M transition and prevented PCM fragmentation in siSTARD9 cells (Figure S7C , top panels) (Vassilev et al., 2006) . Additionally, STARD9 did not localize to daughter centrioles in G2/M arrested cells (Figure S7C , lower panel), confirming our previous results showing STARD9 localization to daughter centrioles only from prophase to late anaphase ( Figure 3C) .
In early mitosis, microtubule-dependent forces are applied to the centrosome by proteins that organize and form the bipolar spindle (Abal et al., 2005) . When PCM cohesion is compromised, these forces fragment the PCM (Oshimori et al., 2006 ). Thus, it was possible that microtubule-dependent forces played a role in the PCM fragmentation observed in siSTARD9 cells. Under normal conditions 80% of siSTARD9 cells exhibit PCM fragmentation compared to 10% of siControl cells (Figure 5D) . However, depolymerization of microtubules with nocodazole treatment drastically reduced PCM fragmentation in siSTARD9 cells to undetectable levels ( Figure S7D, top panels) . Interestingly, stabilization of microtubules in siSTARD9 cells with taxol treatment (interferes with microtubule-dependent forces) also modestly reduced PCM fragmentation (to 51%; Figure S7E , top panels). These results indicate that microtubule-dependent forces drive PCM fragmentation in siSTARD9 cells. In addition, STARD9 was weakly localized to centrioles in taxol treated cells and absent in nocodazole treated cells ( Figure S7D lower panels and S7E, right panels), indicating that the localization of STARD9 to the centrioles requires microtubules. 
STARD9 Depletion Induces Mitotic Apoptosis
Since siSTARD9 cells exhibited elevated levels of mitotic arrest, SAC activation, and apoptosis, we hypothesized that they were apoptosing in mitosis. To test this, we imaged siControl and siS-TARD9 cells by time-lapse microscopy using a HeLa cell line expressing eGFP-histone 2B to mark chromosomes. In control cultures, 90% of cells transitioned through mitosis with normal kinetics (80 min) and 10% had defects in chromosome congression. In contrast, 75% of siSTARD9 cells had defects in chromosome congression and arrested in mitosis for an average of 3.5 hr, at which time their chromatin became fragmented and highly condensed, indicative of apoptosis ( Figures 7A and 7B , Movies S1 and S2). To substantiate our in vivo findings, we tested siSTARD9 cells for biochemical hallmarks of apoptosis, namely DNA fragmentation, apoptosis, and a decrease in cell viability. Synchronized siControl and siSTARD9 cells were fixed 5 hr postmitotic entry and analyzed by the DeadEnd fluorometric TUNEL assay (Promega) for DNA fragmentation (see Supplemental Information). In this assay DNA breaks are labeled with fluorescein-12-dUTP and can be visualized and quantified by fluorescence microscopy. In contrast to siControl cells, siSTARD9 cells had a marked increase in TUNEL-positive cells ( Figure 7C ). Apoptosis relies on the activation of initiator (caspase 9) and effector (caspase 3/7) caspases (Chowdhury et al., 2008) . Thus, we analyzed whether these caspases were activated in siSTARD9 cells. Seventy-two hours posttransfection, asynchronous siControl, siPlk1, or siSTARD9 cells were fixed and the AI was measured as described in our apoptotic screen. Depletion of STARD9 or Plk1 led to an increased AI, confirming our screen results and published data (Petronczki et al., 2008) (Figure 7D ). We then measured the cell viability of siControl and siSTARD9 cells using the CellTiter-Glo assay that measures total ATP levels (indicative of metabolically active cells) at 24, 48, 72, 96, and 120 hr postsiRNA transfection. As expected, the viability of siSTARD9 cells decreased over time compared to siControl cells ( Figure 7E ). These results indicate that STARD9 depletion leads to mitotic arrest, activation of apoptosis and mitotic cell death.
STARD9 Depletion Synergizes with Taxol Treatment
Although paclitaxel (Taxol) remains one of the most widely used anticancer agents, its efficacy is limited by neutropenia and neurotoxicities. If a combination treatment were to shift the dose-efficacy curve, it might be possible to improve the therapeutic index and efficacy of taxol. Thus, we asked if depletion of STARD9 could synergize with taxol to induce apoptosis. siControl and siSTARD9 cells were treated with increasing concentrations of taxol 48 hr posttransfection and their AI was measured 72 hr posttransfection. Indeed, depletion of STARD9 increased the apoptotic response with increasing concentrations of taxol, with an IC 50 of 1.15 mM for siSTARD9 and IC 50 of 3.28 mM for siControl ( Figure 7F ). siSTARD9 treatment also increased the peak AI by 1.73, consistent with a higher percentage of cells undergoing apoptosis at this time point. These results indicate that depletion of STARD9 synergizes with taxol treatment.
The SAC including Mad2 and BUBR1 plays a critical role in the induction of mitotic apoptosis. Thus, we asked if siSTARD9-induced apoptosis was dependent on the SAC by depleting BUBR1 and assessing its effect on the siSTARD9-taxol combination treatment. In comparison to siSTARD9, codepletion of STARD9 and BUBR1 led to a marked decrease in AI ( Figure 7F ), indicating that the SAC plays a critical role in the induction of mitotic apoptosis in siSTARD9 cells. Furthermore, addition of ZVAD, caspase inhibitor, led to a complete inhibition of siS-TARD9-induced apoptosis ( Figure 7F ).
DISCUSSION
The importance of mitotic spindle assembly to cell division and cancer biology has fueled intensive study of this structure. Our interest in identifying targets for cancer therapeutics prompted us to conduct a focused screen for regulators of mitosis. We report the identification of 592 mitotic microtubule copurifying proteins by mass spectrometry and analysis of their contribution to mitosis by functional RNAi screens for mitotic arrest, checkpoint bypass, and induction of apoptosis. Interestingly, we identified a kinesin, STARD9, with a critical role in cancer cell division. Several insights have emerged from our studies. First, we have uncovered a previously undescribed mitotic kinesin whose localization and function is unique and significantly different from other kinesins. Second, based on STARD9s function and enzymatic activity, it appears to be a potential cancer target. Third, the triggers that induce mitotic apoptosis are poorly-defined and our study indicates that compromising the integrity of the PCM may have a role in inducing apoptosis. Finally, our study highlights the utility of performing focused siRNA screens to understand cellular processes, as many of the genes we have identified as regulating mitosis and apoptosis were not identified in previous genome-wide screens for mitotic regulators (Kittler et al., 2007) .
Role of STARD9 in Mitosis STARD9-depletion shares many phenotypic similarities to depletion of Kizuna, a centrosomal protein critical for centrosome integrity and spindle bipolarity, which forms a bond that tethers the expanded PCM to the centriole (Oshimori et al., 2006) . Kizuna is also a Plk1 substrate and functions downstream of Plk1-mediated PCM organization in early mitosis (Oshimori et al., 2006) . Similar to Kizuna, we hypothesize that STARD9 stabilizes the PCM under microtubule-mediated tension during bipolar spindle assembly. However, the localization of STARD9 to centrioles indicates that unlike Kizuna, which forms a general PCM bond, STARD9 may form a link between the daughter centriole and the PCM. Interestingly, both Kizuna and STARD9 are conserved among vertebrates, but not invertebrates or other lower eukaryotes ( Figure S2 ). It is intriguing to consider whether higher eukaryotes may have more sophisticated centrosome compositions that allow them to accommodate the microtubule-mediated tension that occurs during the formation of a bipolar spindle.
Identification of STARD9 interacting proteins will be critical to understanding its role in mitosis. A recent genome-wide yeast two-hybrid analysis identified an interaction between STARD9 and CDK5RAP2 (the human homolog of D. melanogaster Centrosomin) (Stelzl et al., 2005) . CDK5RAP2 localizes to centrosomes during mitosis and has been implicated in centriole engagement, PCM cohesion, and microtubule nucleation (Barrera et al., 2010; Choi et al., 2010) . However, a detailed analysis will be necessary to determine if the STARD9-CDK5RAP2 interaction is important for PCM cohesion. Future efforts to define the mechanism of STARD9s' function will benefit from biochemical purifications and mass spectrometry analyses aimed at identifying STARD9 interacting proteins, which may cooperate with STARD9 or regulate STARD9 activity.
The localization of STARD9 to daughter centrioles is unique, as centrobin is the only protein known to predominantly localize to daughter centrioles (Zou et al., 2005) . However, unlike centrobin, STARD9 centriolar localization is cell-cycle-regulated, appearing only at the onset of prophase and disappearing by cytokinesis ( Figure 3C ). Treatment with nocodazole abolishes this localization indicating that it is microtubule-dependent ( Figure S7D ). Interestingly, the STARD9 motor domain displays microtubule binding and ATPase activities, both of which are required for its centriolar localization ( Figure 4C ).
STARD9 Depletion and Apoptosis
The triggers that activate the apoptotic pathway in mitosis are poorly understood. Interestingly, Plk1 and Kinesin-5 inhibitors tend to arrest the cells in mitosis for prolonged lengths of time (up to 18 hr) before the induction of apoptosis (Petronczki et al., 2008; Shi et al., 2008) . However, the induction of apoptosis observed in STARD9-depleted cells appears to show rapid kinetics, implying that siSTARD9 prometaphase arrest differs from that observed in Plk1 and Kinesin-5 inhibited cells. It is tempting to consider that PCM fragmentation, defective microtubule dynamics, or DNA tearing observed in STARD9-depleted cells (Figures 5 and 7) are important apoptotic triggers and should be explored further.
STARD9 as a Cancer Target
Several of our findings indicate that inhibition of STARD9s enzymatic activity may be a viable approach to inhibiting cancer cell division. First, the PCM fragmentation and spindle assembly defects caused by STARD9-depletion appear to be conserved among multiple cancer cell lines and not in normal cell lines (Figure 5E and S4) . Second, siSTARD9 cells apoptose during mitosis and with faster kinetics than other antimitotic treatments like Kinesin-5 or Plk1 inhibition. Third, the STARD9 microtubule binding and ATPase activities are critical to its localization to centrioles and function in PCM cohesion ( Figures 4C and 5H) . Fourth, depletion of STARD9 synergizes with taxol treatment (Figure 7F ), opening the possibility for combined therapies. Many details of STARD9 function will need to be explored to fully assess its potential as a cancer target, including a structurefunction analysis. In addition, as the basal expression levels of STARD9 do not correlate with the level of STARD9-depletion sensitivity, future studies should be aimed at identifying the variables that lend specific types of cancers responsive to STARD9 inhibition. Finally, it is possible that the low STARD9 levels observed in many cancers could be a contributing factor to cancer progression and should be analyzed further.
EXPERIMENTAL PROCEDURES
Cell Culture HeLa cells were grown in F12:DMEM 50:50 medium (GIBCO) with 10% FBS, 2 mM L-glutamine and antibiotics, in 5% CO 2 at 37 C. To obtain synchronized HeLa cells in mitosis, cells were treated with 300 nM nocodazole (SigmaAldrich) for 18 hr. To synchronize HeLa cells in G1/S, cells were treated with 2 mM thymidine (Sigma-Aldrich) for 18 hr. For in vivo small molecule inhibition, cells were incubated with 100 mM Monastrol (Sigma-Aldrich) (Kinesin-5 inhibition), 200 nM compound 1 (GlaxoSmithKline) (Plk1 inhibition), 10 mM R0-3306 (EMD Chemicals) (Cdk1 inhibition), 5 mM taxol, or 300 nM nocodazole 6 hr postrelease, fixed, and stained 4 hr post-small-molecule addition. For gene knockdowns, cells were transfected with indicated Dharmacon ONTARGETplus siRNA at 50 nM using Lipofectamine RNAiMAX (Invitrogen) for 48 hr.
Microtubule Aster Copurifying Proteins
Mitotic aster microtubule copelleting assays were performed essentially as described in (Mack and Compton, 2001) . Sixteen 15 cm plates of nocodazole (300 nM for 18 hr) arrested mitotic HeLa cells were harvested by mitotic shakeoff, washed in PBS plus 20 mg/ml cytochalasin B (Sigma-Aldrich) twice, washed with KHMD (78 mM KCL, 50 mM HEPES [pH 7.0], 4 mM MgCl 2 , 2 mM EGTA, 1 mM DTT, 20 mg/ml cytochalasin B) once and resuspended in KHMDL (KHMD plus protease inhibitors leupeptin-pepstatin-chymostatin 1 mg/ml). Cells were dounce homogenized and extracts were cleared by ultracentrifugation at 38,000 RPM for 15 min. All steps were carried out at 4 C unless otherwise noted. Cleared lysates were supplemented with 5 mg/ml latrunculin B (Sigma-Aldrich). Microtubule polymerization reactions were carried out in the presence of control vehicle DMSO or 10 mM taxol (SigmaAldrich) at 33 C for 30 min. Polymerization reactions were layered onto a 50% W/V sucrose/KHM cushion supplemented with 10 mM taxol for reactions with taxol-stabilized microtubules. Layered reactions were centrifuged for 2 hr at 39,000 RPM in a TLS-55 (Beckman) swinging bucket ultracentrifuge rotor. The microtubule copelleting fraction was washed three times with KHM buffer and processed for LC-MS/MS analysis (see Extended Experimental Procedures).
RNAi Screen Conditions
Dharmacon ON-TARGETplus siRNA smart pools and individual oligos targeting the MMCP gene set were arrayed on 96-well plates. For transfection, Oligofectamine (Invitrogen) in OPTI-MEM (Invitrogen) was added to each well of a 96-well plate (poly-D-Lysine coated, Beckton Dickinson Labware) containing the prespotted siRNA library. The mixture was incubated for 40 min and HeLa cells, 10,000 cells/well, were plated onto the siRNA mixture using a multidrop combi (Thermo Scientific) to ensure even distribution. Cells were incubated at 37 C for indicated times. For + taxol screens, taxol (100 nM final concentration) was added to each well 24 hr posttransfection using a RapidPlate liquid handler (Caliper Life Sciences). For mitotic arrest screens, 48 hr posttransfection cells were fixed by paraformaldehyde (4% final concentration) perfusion for 15 min at room temperature. Following fixation, cells were permeabilized with .2% Triton X-100/PBS for 5 min at room temperature.
Plates were washed with PBS one time and stained for phosphohistone H3
(F) Depletion of STARD9 synergizes with taxol treatment and is dependent on the spindle assembly checkpoint. Cells treated with control, STARD9, BUBR1, or STARD9 + BUBR1 siRNA were incubated with increasing concentrations (0-10 mm) of taxol and the apoptotic index was quantified as in D. Additionally, the small molecule ZVAD was added to STARD9 siRNA-treated cells. Figure S7 , and Movies S1 and S2.
and DNA (1:50 Alexa 488 phosphohistone H3 (Ser10) (Cell Signaling) and 1 mg/ml Hoechst 33342 in 5% fish gelatin (Invitrogen) for 1 hr. After staining plates were washed two times with .1% Triton X-100/TBS using a BioTek microplate washer ELx405 (BioTek Instruments). Screen plates were imaged on a Cellomics ArrayScanVTI HCS Reader (Cellomics). The ArrayScan/ vHCS:Scan software was used for image acquisition using the following parameters: objective: 103 .5 NA, bio application algorithm: Spot Detector, number of channels: two Hoechst and FITC, focus channel: Hoechst, scan limits: 1,000 objects (nuclei), with background correction and object segmentation on. Data was analyzed using ArrayScan/vHCS:View software and exported to Excel spreadsheets. For apoptotic screens, 72 hr posttransfection cells were fixed and subjected to the Caspase-Glo assay (Promega) or the CellTiter-Glo assay (Promega) and the apoptotic index (AI, caspase activity per cell/ATP levels as described in (Peterson et al., 2010) was measured using a luminometer. For statistical analysis, see Extended Experimental Procedures.
Motor Domain Analysis
For STARD9 motor domain expression (modified from (Moyer et al., 1996) , microtubule-binding assays (as described in (Goode and Feinstein, 1994) , centrosome binding assays (as described in (Mitchison and Kirschner, 1986) , ATPase assays (as described in (Funk et al., 2004) , localization studies, and rescue experiments, the first 387 amino acids of STARD9 (WT, T110N, and R223A) were fused to the C terminus of either GST (pGEX-6P vector) or eGFP (pGLAP1 vector, (Torres et al., 2009 ). For localization, overexpression, and rescue experiments, eGFP, or eGFP-tagged STARD9-MD-WT, T110N, or R223A were transfected in to HeLa cells for the indicated times. Cells were fixed and stained for DNA, a-tubulin, eGFP, and pericentrin. For centrosome binding experiments, 100 mg of GST-STARD9-MD or GST-Skp1, were prebound to glutathione agarose beads, and incubated with 500 mg of mitotic centrosome preps, after 1 hr beads were pelleted, washed three times with 110 mM NaCl, 5mM ATP, 80mM PIPES (pH 6.9), 5mM MgCl2, 1mM EGTA, and samples from the first supernatant and the pellet fraction were resolved by SDS-PAGE and analyzed by immunoblot with indicated antibodies.
Immunofluorescence
Immunofluorescence was carried out essentially as described in (Torres et al., 2010) . HeLa cells were transfected with control or indicated siRNA (ONTARGETplus siRNA, Dharmacon) for 48 hr, fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100/PBS, and costained with 0.5 mg/ml Hoechst 33342 and indicated antibodies. Images were captured with a Zeiss Axio Imager.Z1 microscope and processed using SlideBook 4.2 (Intelligent Imaging).
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